Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

Preoperative immunotherapy for mesothelioma shows favorable outcomes

December 15, 2022 By Thomas Lamb

In a study published recently in the journal Clinical Cancer Research, researchers at Baylor College of Medicine found that treating patients who have resectable malignant pleural mesothelioma, meaning that their tumor can be removed with surgery, with immunotherapy ahead of surgery resulted in favorable clinical outcomes. The study lays the … [Read more...]

Filed Under: Mesothelioma Tagged With: Immune checkpoint inhibitor (ICI), Immunotherapy, malignant pleural mesothelioma (MPM), mesothelioma treatments

Pembrolizumab/Lenvatinib Combo Shows Positive Clinical Activity in Recurrent Pleural Mesothelioma

September 13, 2022 By Thomas Lamb

The combination of pembrolizumab (Keytruda), and lenvatinib (Lenvima) demonstrated promising clinical activity with no unexpected toxicities in patients with malignant pleural mesothelioma (MPM), according to results from the PEMMELA study (NCT04287829) presented at the International Association for the Study of Lung Cancer 2022 World … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Keytruda, Lenvima, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Galinpepimut-S Plus Nivolumab Extends Survival in Malignant Pleural Mesothelioma

August 3, 2022 By Thomas Lamb

The combination of galinpepimut-S and nivolumab (Opdivo) was found to extend survival in patients with malignant pleural mesothelioma who were either refractory to, or who had relapsed after, at least 1 line of standard therapy, according to updated data from a phase 1 trial (NCT04040231). The median overall survival (OS), which was calculated … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Galinpepimut-S, malignant pleural mesothelioma (MPM), mesothelioma treatments, Opdivo

Second Surgery for Recurrent Malignant Pleural Mesothelioma after Multimodality Treatment: A Systematic Review

June 30, 2022 By Thomas Lamb

Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related tumour with poor prognosis. To date, a multimodality treatment, including chemotherapy and surgery, with or without radiotherapy, is the gold standard therapy for selected patients with epithelioid and early-stage MPM. In this setting, the goal of surgery is to achieve the … [Read more...]

Filed Under: Asbestos, Medicine, Mesothelioma Tagged With: asbestos, asbestos exposure, asbestos-related cancer, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Abemaciclib for Previously Treated Patients With p16ink4A-Deficient Mesothelioma

April 15, 2022 By Thomas Lamb

As reported in The Lancet Oncology by Dean A. Fennell, FRCP, and colleagues, a phase II trial (MiST2) showed the activity of [ Verzenio (abemaciclib) ] in previously treated patients with p16ink4A-deficient malignant mesothelioma. As stated by the investigators, “Genetically stratified therapy for malignant mesothelioma is unavailable. … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: abemaciclib, malignant mesothelioma, mesothelioma, mesothelioma treatments, Verzenio

Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesothelioma

March 11, 2022 By Thomas Lamb

[Verzenio (abemaciclib), a drug that has proven effective in breast cancer,] showed preliminary activity in its first-ever clinical trial in mesothelioma. The cyclin-dependent kinase (CDK) 4/6 inhibitor [Verzenio (abemaciclib)] achieved disease control at 12 weeks in 14 of 26 patients with progressive mesothelioma associated with a CDKN2A … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: abemaciclib, malignant mesothelioma, mesothelioma, mesothelioma treatments, Verzenio

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

February 21, 2022 By Thomas Lamb

Background: In the phase 3 CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma [(unresectable MPM)]. We report updated data with 3-year minimum follow-up. Patients and methods: Adults with previously … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study

February 14, 2022 By Thomas Lamb

Introduction:  Malignant mesothelioma (MM) is an aggressive cancer that primarily arises from the pleura (MPM) or peritoneum (MPeM), mostly due to asbestos exposure. This study reviewed the Dutch population-based incidence, treatment and survival since the national ban on asbestos in 1993. Materials and methods:  Patients with MPM or MPeM … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: asbestos exposure, malignant mesothelioma, mesothelioma, mesothelioma diagnosis, mesothelioma treatments, peritoneal mesothelioma, pleural mesothelioma

Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma

January 11, 2022 By Thomas Lamb

We compared less invasive surgery with conventional surgery for malignant pleural mesothelioma (MPM). We retrospectively reviewed consecutive patients with MPM who received surgery at Hyogo College of Medicine between July 2004 and April 2016. Patients underwent multimodal treatment comprising chemotherapy (neoadjuvant and/or adjuvant) and surgery … [Read more...]

Filed Under: Medicine, Mesothelioma, Uncategorized Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Immune Checkpoint Inhibitors Extend Survival for Mesothelioma

December 29, 2021 By Thomas Lamb

Immune checkpoint inhibitor (ICI) therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma (MPM), offering more effective and less toxic treatment options for patients. The research and clinical oncology communities eagerly await the completion of several upcoming trials focused on … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Immune checkpoint inhibitor (ICI), malignant pleural mesothelioma (MPM), mesothelioma treatments

Next Page »

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Who Was Exposed to Asbestos
  • NC Asbestos Exposure Sites
  • Asbestos-Contaminated Talc
  • Asbestos Diseases
  • Legal Compensation
  • Free Case Evaluation
  • Frequently Asked Questions
  • About Our Law Firm
  • Attorney Tom Lamb
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

Lamb Law Office

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.